Oncology Pharma Inc.
ONPH · OTC
3/31/2022 | 3/31/2021 | 3/31/2020 | 3/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.00 | 0.19 | 0.00 |
| FCF Yield | 0.33% | -0.04% | -0.67% | -1.23% |
| EV / EBITDA | -14,430.23 | -20.28 | -19.23 | -3.97 |
| Quality | ||||
| ROIC | -3.24% | -21,078.36% | -614.30% | -3,219.80% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.00 | 0.00 | 0.11 | 0.04 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 414.85% | -422.33% | 39.27% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -83.53 | -0.02 | -0.70 | -0.28 |
| Interest Coverage | -0.00 | -0.17 | -16.16 | -25.97 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |